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Eosinophilic nasosinusal polyposis is a chronic inflammatory 
infection with elevated infiltration of eosinophils, which 
presents high rate of recurrence after surgical treatment. 
The continuous inflammatory process that leads to the 
formation of polyps requires constant clinical treatment. 
Contributing to the maintenance of eosinophilia are cytokines 
IL5 (interleukin-5) and GM-CSF (granulocyte macrophages 
colony-stimulating factor), which show up in elevated 
concentrations. These oligoproteins diminish the rate of 
apoptosis and prolong the survival of eosinophils. Aim: 
By diminishing these cytokines, the action of Mitomycin C 
(MMC), an antineoplasic drug which inhibits the synthesis 
of DNA, was studied. In a recent study the power of this 
drug to cause apoptosis in eosinophils, in vitro, of nasal 
polyps was verified. Methodology: A biopsy of the nasal 
polyps was undertaken in 15 patients carriers of eosinophilic 
nasosinusal polyposis 24 hours after applying 0.5 mg/ml 
of MMC during five minutes. RT-PCR (reverse transcription 
of polymerase chain reaction) for IL5 and GM-CSF was the 
method used to obtain the results. Results: The comparison 
of the results of GM-CSF pre- and post-application of MMC, 
when the paired T-test was used, showed p=0.041 and for 
IL5 we found p<0.001. Conclusion: Topic use of MMC 
in patients with eosinophilic nasosinusal polyposis shows 
statistically significant reduction for GM-CSF and significant 
and important reduction for IL5.
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INTRODUCTION
Naso-Sinus Polyposis (NSP) – eosinophylic NSP – is 
a chronic proliferative inflammatory disease that affects 
the nasal and nasal sinuses mucosa, and is characterized 
by a benign polypoid degeneration (Figure 1). It is usu-
ally bilateral, has its incidence peak on the fourth decade 
of life and affects 2.7% of the population, with a 2.2:1 
male/female ratio. It is strongly associated to asthma; 1/3 
of eosinophilic NSP patients have asthma, therefore, the 
complete exam of the respiratory tract should be a rou-
tine. It is also related to NAER (non-allergic eosinophilic 
rhinitis), aspirin intolerance, alergic fungal sinusitis and 
Churg-Strausss syndrome1,2.
They are Histologically characterized by eosi-
nophilic granulocytes of which the pathogenic mechanism 
is not entirely known. They also bear morphologic altera-
tions such as nasal membrane hyperplasia, irregularity 
of gland distribution, squamous metaplasia and edema 
(Figure 2)3,4.
Although it has been related to IgE mediated 
hypersensitivity, or nasal allergy, studies have shown 
that allergy is only one possible cause or a contributing 
factor5-7. Eosinophil and polyp structural cells secrete cy-
tokines that maintain the inflammation process and the 
Eosinophil build up constant. 8 Cytokines such as IL5 
and GM-CSF increase eosinophil survival and prolong 
their presence within the polypoid tissue, reducing the 
apoptosis rates of these cells9-12.
Eosinophils express CD40 receptor for this GM-CSF 
and CD40L autocrine production and they are expressed 
by T CD4 cells that are present in eosinophilic NSP13.
The high IL5 concentration found on eosinophilic 
NSP suggests an autocrine effect for this cytokine in eosi-
nophil activation, there still is a strong relation between 
IL5 and ECP (eosinophilic cationic protein)10,14.
This cytokine increase is related to the genetic as-
pect of the NSP eosinophilic cells5.
Most of the treatment available is based on the use 
of systemic steroids for a short duration and topical steroid 
for a longer period, besides surgery15.
MMC is an antineoplastic agent produced by the 
Streptomyces caespitosus that has been used as antiprolif-
erative agent in the 0.4mg/ml concentration. When used 
after surgery, its action on fibroblasts leads to a reduction 
in scar tissue formation. It has a time-dependent action 
e its application for 5 minutes has a measurable effect 
on cell morphology and proliferation for up to 36 days 
in vitro16. MMC mechanism of action is based on the 
selective induction of DNA synthesis, recombination and 
exchange of “sister” chromatin. Its association with other 
anti-tumoral drugs leads to an increase in its cytotoxic ef-
fect by increasing apoptosis induction17-19.
Crosara et al. (2004) showed that MMC is efficient 
in inducing the apoptosis of eosinophils present in the 
stroma of eosinophilic nasal polyps in vitro. Paired studies 
with nine cultivated samples were carried out. The polyps 
were treated with 0.4mg/ml for five minutes and were 
dyed with hematoxylin eosine15.
In topical use, this drug has been used in ophthal-
mology, otology and laryngology without systemic toxicity, 
thus being considered safe. It does not cause bleeding, 
necrosis or infection when used in external acriocistorhi-
nostomy or permanent eyelash lesions in concentrations 
of up to 1mg/ml16,18,20-27.
This study aims at assessing MMC action, in vivo, 
in patients with eosinophilic NSP through IL5 and GM-
CSF analysis, pre and 24hs post application, using RT-PCR 
(reverse transcription in polymerase chain reaction).
MATERIALS AND METHODS 
This investigation was made up of eosinophilic 
NSP patients who agreed to participate in the study, after 
approval by the Research Ethics Committee. The variables 
were made up of GM-CSF and IL5 profiles. 15 patients 
were studied, 6 women and 9 men. Their ages varied 
from 30 to 57 years.
As inclusion criteria, we used: presence of eosi-
nophilic NSP and no aspirin intolerance. Eosinophilic pol-
yps were considered when tissue eosinophylia as greater 
then 30% among inflammatory cells, determined by finding 
at least four eosinophils in each large magnification mi-
croscopic field28. Patients with previous history of aspirin 
intolerance, who underwent previous surgery or severe 
steroid-dependent asthma patients were excluded.
The patients selected underwent MMC application 
on the right nasal cavity polyps in the concentration of 
0.5mg/ml in a cotton ball wet with 1 ml of the drug, where 
it remained for five minutes. The left nasal cavity was the 
control-group, considered as pre-use.
PCR biopsies after 24h of MMC use were made in the 
right nasal cavity and, following that, in the left nasal cavity 
as well. Tissues collected had average size of 10mm, were 
then immediately taken to the University Immunology lab 
where they remained stored at 80 degrees below zero.
The cytokines profile was checked on the polypoid 
tissue through reverse transcription in polymerase chain 
reaction (RT-PCR) for IL5 and GM-CSF.
Primer sequence used in the PCRs 
Gene Forward Reverse GM-CSF AGAAATGTTTGAC-
CTCCAGGA TTGCACAGGAAGTTTCCG IL 5 CTGAGGAT-
TCCTGTTCCTGT CAACTTTCTATTATCCACTC 
The PCR products were analyzed by electrophoresis 
in silver dyed 8% polyacrylamide gel. The gels were photo-
graphed using the AlphaDigiDoc 1201 photo-documenta-
tion system, and the PCR resulting bands for each sample 
were analyzed by densitometry, using the AlphaEaseFC 
software version 3.3.0 (Alphalnnotech) (Figure 3). This 
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software calculates the IDV - Integrated Density Value for 
each band, and it is defined as the pixel intensity in the 
region outlined by the band, subtracted from the pixel 
intensity of the bottom color of the gel band.
RESULTS 
Regarding the values obtained for IL5, in Figure 4 
we see the box-plot distribution chart before and after 
MMC use. We see that 75% (upper part of the box) of 
IL5 values after MMC are below 3,000 while almost 100% 
(lower chart line before) of the IL5 pre MMC values are 
above this value.
Comparing the IL5 average pre and post, using 
the paired t test we saw a p<0.001, indicating important 
statistical significance.
In relation to the GM-CSF values on Figure 5, we 
see the box-plot chart of the GM-CSF pre and post MMC 
application distribution values and notice that 75% (upper 
box) of GM-CSF values are below 15,000 while only 50% 
of the GM-CSF pre MMC values are below this threshold 
(middle line of the pre MMC chart).  The average pre and 
post GM-CSF comparison using the paired t test, showed 
a p =0.041. Thus, the observed difference does bear sta-
tistical significance.
Figure 6 shows GM-CSF and IL5 percentage reduc-
tion in the distribution values box-plot chart. We can see 
that practically over 75% of patients had an IL5 reduction 
above 60%, because the box line is somewhat below this 
value and that 75% of the patients had a GM-CSF reduc-
tion below 60%, because the upper box line is somewhat 
below this value.
Table 1 shows the Pearson’s correlation coefficient 
for IL5 and CM-CSF variation percentage comparison with 
the continuous variables.
No statistically significant correlation was observed, 
in other words, the IL5 and GM-CSF percentage variation 
reduction was not followed suit by the variation of any 
of the other variables.
DISCUSSION 
The participation of polymorph nuclear cells in the 
nasal mucosa epithelial interface and in other nose diseases 
is well understood. The increase in cytokine concentrations 
proves its inflammatory nature. Eosinophils are sources of 
interleukins that bear autocrine and modulator effect on 
the function of other cells14.  The continuity of the inflam-
matory response seen in the eosinophylic NSP is related to 
cytokines such as IL5 and GM-CSF which increase survival 
and reduce the eosinophil apoptosis rate7,8,10-12.
Therefore, they regulate proliferation and cell ac-
Figure 1. Polyps in an eosinophylic polyposis patient; endoscopic 
view.
Figure 2. Histology cross-section of an eosinophylic polyp.  Stroma 
bearing eosinophils, lymphocytes and edema.
Figure 3. IL5 and GM-CSF PCR results before and after MMC.
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Table 1. Correlation and determination coefficient among the continu-
ous variables.
 R r2 p
% IL5 reduction    
Age 0,28 0,045 0,446
Eosinophils 0,112 0,013 0,691
GMCSF reduction 0,039 0,002 0,899
% GMCSF reduction    
Age 0,125 0,016 0,683
Eosinophils 0,174 0,030 0,570
IL5 reduction 0,039 0,002 0,899
Source: study data
Figure 4. box-plot chart showing the IL5 values before and after 
MMC.
Figure 6. box-plot chart showing the GM-CSF and IL5 reduction 
percentage.
Figure 5. box-plot chart showing the GM-CSF values before and after 
MMC.
tivation, broadening local immune response and polyp 
formation. Eosinophils express IL5 in all eosinophylic NSP 
and, approximately 30% of the eosinophils have genetic 
expression for GM-CSF, with evidences of autocrine effect 
for these citokines14. The eosinophil clearance would be 
a mechanism to reduce the inflammatory process. The 
cytokine production is related to the tissue cell phenotype, 
and numerous studies show the key participation of IL5 
and GM-CSF in maintaining the inflammatory activity. 
Therefore, blocking these cytokines would be a therapeutic 
way to improve this condition. One single MMC application 
for five minutes has a measurable effect on cell morphol-
ogy and proliferation for up to 36 days in vitro16.
Crossara et al. Showed that MMC is efficient in 
inducing eosinophil apoptosis when these are present in 
the stroma of eosinophylic nasal polyps. A paired study 
with nine cultivated samples was carried out and we ob-
served that the MMC treated cultures presented 12-hour 
apoptosis rate significantly higher in relation to the control 
group (p<0.001)15.
MMC proved to have inhibitory action on DNA 
synthesis, inhibiting the proliferation of many cell lines. 
Kim et al. showed that its anti human-cultivated-fibroblasts 
effect may be mediated not only by the antiproliferative 
action, but also by the degree of apoptosis induced21.
Our goal in this study was to show MMC action 
in reducing the concentration of major cytokines that act 
in maintaining the eosinophylic NSP inflammatory proc-
ess. Such study has not yet been found in the medical 
literature.
The paired t test showed that the post MMC GM-
CSF values were significantly lower than the pre values 
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(p=0.041). Comparing IL5 values pre and post MMC, we 
found one important reduction: the medication was ef-
ficient in reducing the concentration of these substances. 
Comparing the percentage with the other variables, we 
did not observe any variable that would present significant 
correlation.
MMC may be an option in the pos-surgical treat-
ment of eosinophylic NSP. Further studies are necessary 
to better use this drug against this disease.
CONCLUSION
As to the action of MMC over the main cytokines 
involved in NSP inflammatory process and in relation to the 
age and percentage of eosinophils, we concluded that: 
1. The IL5 post MMC use values were lower than 
pre MMC use, with important statistical significance;
2. The GM-CSF post MMC use values were lower 
than pre MMC use, with statistical significance.
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